Multiple Myeloma, MM

Clinical Roundup: Gene-Edited CAR T Therapies

Mar. 31, 2021

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Clinical Trial Update: Gene-edited CAR T Therapies

Mar. 17, 2021

This week’s clinical update looks at 3 clinical trials for CRISPR-edited CAR T therapies for the treatment of B-cell cancers or multiple myeloma.

Gene-Editing IND and Pre-clinical Update

Dec. 23, 2020

Update on Allogene Therapeutics off-the-shelf CAR-T cancer therapies. This week’s gene-editing update looks at an investigational new drug (IND)...

Latest Gene Editing Clinical Trials for Cancer

Nov. 12, 2020

We have added 6 new cancer trials to our overview of current clinical trials involving gene editing.

Latest Gene editing Clinical Trials

Aug. 12, 2020

We have added two cancer immunotherapy trials to our overview of current clinical trials involving gene editing.

Multiple Myeloma, MM

Multiple Myeloma, MM, (NCT03752541)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (ALLO-605)
Sponsors:
Allogene Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT04171843)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT04093596)
Sponsors:
Allogene Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT04142619)
Sponsors:
Cellectis S.A.

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT04244656)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT03399448)
Sponsors:
University of Pennsylvania

IND Enabling

Phase I

Phase II

Phase III